Skip to main content
Colorado General AssemblyToggle Main Menu
Agency NameToggle Agency Menu

42785C456712F10A872587F400769908 Hearing Summary




PUBLIC
BILL SUMMARY For CU CANCER CENTER PRESENTATION ON BREAKTHROUGH RESEARCH IN THE TREATMENT OF LEUKEMIA

HOUSE COMMITTEE ON PUBLIC & BEHAVIORAL HEALTH & HUMAN SERVICES
Date Feb 25, 2022      
Location HCR 0112



CU Cancer Center Presentation on Breakthrough Research in the Treatment of Leukemia - Committee Discussion Only


02:35:28 PM  

Jerry Johnson, University of Colorado, provided an introduction to the presentation on cancer research. Dr. Daniel Pollyea, Division of Hematology, School of Medicine, University of Colorado (CU) - Anschutz Medical Campus, presented to the committee on research in the treatment of leukemia. He provided a powerpoint the committee (Attachment D). He discussed statistics related to acute myeloid leukemia (AML) and the challenges to historic treatments for AML. Dr. Pollyea discussed the development of the CU Leukemia Program that is targeting and destroying leukemia stem cells.

02:46:38 PM  

Dr. Pollyea discussed the related clinical trials for the treatment and the approval of venetoclax treatment by the Federal Drug Administration. He stated that the venetoclax treatment is now the standard of care around the world. Dr. Pollyea discussed how CU has become leaders in leukemia stem cell research, the related grant funding, and the recruitment opportunites and jobs the research has allowed for at the campus.  The following link to a short video was shared with the committee members:  https://news.cuanschutz.edu/news-stories/this-is-breakthrough-dr.-dan-pollyea.






The effective date for bills enacted without a safety clause is August 7, 2024, if the General Assembly adjourns sine die on May 8, 2024, unless otherwise specified. Details